Model-Based Meta-Analysis of Relapsing Mouse Model Studies from the Critical Path to Tuberculosis Drug Regimens Initiative Database
Alexander Berg, James Clary, Debra Hanna, Eric Nuermberger, Anne Lenaerts, Nicole Ammerman, Michelle Ramey, Dan Hartley, et al. (9 authors)
Antimicrobial Agents and Chemotherapy · 2022-01
Abstract
Tuberculosis (TB), the disease caused by Mycobacterium tuberculosis (Mtb), remains a leading infectious disease-related cause of death worldwide, necessitating the development of new and improved treatment regimens. Nonclinical evaluation of candidate drug combinations via the relapsing mouse model (RMM) is an important step in regimen development, through which candidate regimens that provide the greatest decrease in the probability of relapse following treatment in mice may be identified for further development.
MeSH terms
- Tuberculosis
- Medicine
- Regimen
- Drug
- Intensive care medicine
- Disease
- Database
- Drug development
- Immunology
- Tb treatment
- Infectious disease (medical specialty)
- Pharmacology
- Pharmacotherapy
- Mycobacterium tuberculosis
- Cause of death
- MEDLINE
- Internal medicine